泼尼松对肾病综合征患儿骨合成分子标志物的影响  

Effect of glucocorticoid on molecular markers of bone formation in children with nephrotic syndrome

作　　者：徐青[1] 戎赞华[1] 窦志艳[1] 乔丽敏[1] 张玉华[1] 田秀巧[1] 张会丰[1] 

机构地区：[1]河北医科大学附属第二医院儿科,石家庄050000

出　　处：《实用儿科临床杂志》2003年第9期691-692,共2页Journal of Applied Clinical Pediatrics

摘　　要：目的　探讨糖皮质激素对肾病综合征 (NS)征患儿骨合成分子标志物的影响。方法　以I型前胶原羧基端前肽 (PICP)、骨钙蛋白 (BGP)及碱性磷酸酶 (AKP)为参数 ,对单纯性NS患儿泼尼松治疗前及治疗 3～4周后骨合成状况进行探讨。结果　泼尼松治疗后PICP、BGP、AKP与治疗前相比有显著差异 ,治疗后低于治疗前水平 [PICP(P <0 .0 1)、BGP(P <0 .0 1)、AKP(P <0 .0 1) ]。Objective To explore the effects of glucocorticoid on bone formation in children with nephrotic syndrome.Methods Molecular markers-serum procollagen type I c-terminal propeptide (PICP),serum osteocalin (BGP) and totoal alkaline phosphatase (AKP) were taken as the markers, and bone formation was observed before prednison-pretreatment and during prednison-pretreatment 3-4 weeks in children with nephrotic syndrome.Results There was significant difference before and after the treatment with prednison administration ;the markers of bone formation were [PICP(90.41±50.13 to 172.82±82.06 μg/L,P<0.01)、BGP( 6.26 ±2.67 to 14.59±7.08 μg/L,P<0.01)、AKP(91.92±34.37 to 209.08±62.97 U/L,P<0.01)].Conclusion High dose of glucocorticoid can completely inhibit bone synthesis in children with nephrotic syndrome.

关 键 词：儿童 肾变病综合征 糖皮质激素 骨合成 胶原 骨钙蛋白 

分 类 号：R726.9[医药卫生—儿科]